PEARL DIAGNOSTICS, INC.

BALTIMORE, MD · Founded 2022 · CIK 0001922830 · Medtech · Private

MycoMEIA, an enzyme immunoassay that detects fungal galactofuranose antigens in urine to diagnose aspergillosis

pearldx.com →
Grants
$3.9M
4 awards
Sector median: 1
Raised
$15M
2 Form D · Apr 2026
6 months since last filing
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Urine Diagnostics for Aspergillosis$238,175
Federal grantDepartment of Health and Human Services · Phase II · Urine Diagnostics for Aspergillosis$1,844,235
Federal grantDepartment of Health and Human Services · Phase II · Urine Diagnostics for Aspergillosis$840,042
Federal grantDepartment of Health and Human Services · Phase II · MycoMEIA - Urine Diagnostic for Aspergillosis$976,576
Private capital raisedForm D · SEC$3,525,000
Private capital raisedForm D · SEC$11,150,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1467Adialante——
1468RADIATION DETECTION SOLUTIONS LLC——
1469Healthy America, LLC—$31M
1470PEARL DIAGNOSTICS, INC.—$15M
1471KULEANA TECHNOLOGY, INC.—$250K
1472MAINELY SENSORS, LLC——
1473Novasenta Inc.—$25M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • John CammackDirector
  • Eric GornsteinDirector · Executive Officer
  • Kieren MarrDirector · Executive Officer
  • Brad SpellbergDirector

Patents

USPTO · 0 granted of 1
  • Methods And Compositions Using Extracellular Vesicles For The Detection Of Disease And Disordersapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.